Bay Colony Advisory Group Inc d b a Bay Colony Advisors Has $2.49 Million Stock Holdings in Johnson & Johnson $JNJ

Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,271 shares of the company’s stock after acquiring an additional 473 shares during the quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Johnson & Johnson were worth $2,485,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Loop Capital set a $190.00 price target on Johnson & Johnson in a research report on Wednesday, October 22nd. Citigroup increased their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Finally, Barclays increased their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Trading Up 1.3%

Shares of JNJ opened at $189.05 on Friday. The business has a 50-day moving average of $183.08 and a 200 day moving average of $167.32. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The firm has a market cap of $455.47 billion, a P/E ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.